AR
MRTX

Advisory Research’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Advisory Research’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,274
Closed -$1.32M – 356
2019
Q4 		$1.32M Buy
10,274
+4,128
+67% +$398K 0.06% 150
2019
Q3 		$479K Sell
6,146
-7,724
-56% -$725K 0.02% 254
2019
Q2 		$1.43M Buy
+13,870
New +$1.08M 0.03% 216

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Advisory Research's MRTX Position: Q1 2020 in Review

Advisory Research sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 10,274 shares — an estimated $1.32M sold.

Advisory Research first reported a position in MRTX in Q2 2019 and held it in 3 quarters. The position peaked at $1.43M in Q2 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

  • Advisory Research reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Advisory Research sold 10,274 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.32M.
  • Advisory Research first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Advisory Research's Mirati Therapeutics, Inc. Common Stock position peaked at $1.43M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Advisory Research's 13F filing for Q1 2020, filed 12 May 2020.